美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Hemab Therapeutics Holdings, Inc.

34.00

+16.0088.89%

盘后：33.10-0.9000-2.65%19:59 EDT

成交量：411.35万

成交额：1.29亿

市值：13.33亿

市盈率：- -

高：36.61

开：27.00

低：27.00

收：18.00

52周最高：36.61

52周最低：27.00

股本：3,920.76万

流通股本：1,176.47万

量比：- -

换手率：34.96%

股息：- -

股息率：- -

净资产收益率：-46.99%

总资产收益率：-30.11%

市净率：-7.55

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Hemab Therapeutics Holdings, Inc.

交易所：

NASDAQ

成立时间：

2020

员工人数：

59

公司地址：

101 Main Street,Suite 1220,Cambridge,Massachusetts,United States

官网：

http://www.hemab.com

邮编：

02142

电话：

传真：

- -

简介：

Hemab Therapeutics Holdings, Inc.于2026年2月12日根据特拉华州法律注册成立。Hemab Therapeutics是一家临床阶段的生物技术公司，致力于开发革新血液凝固障碍治疗的疗法，以帮助维持生命并增强人类的抵抗力。公司的使命是通过发现、开发和商业化创新疗法，为全球患有严重出血和血栓性疾病的患者打造领先的凝血领域公司。这些疾病包括格氏血小板无力症、VII因子缺乏症、血管性血友病以及其他可能造成终身沉重负担的异常出血性疾病。公司的主要候选药物sutacimig (HMB-001) 是一种双特异性抗体，目前正在进行一项针对格氏血小板无力症预防性治疗的I/II期临床试验和一项针对VII因子缺乏症预防性治疗的II期临床试验。

董事

名称

职位

Benny Sorensen

Chief Executive Officer and Director and President

Akshay Vaishnaw

Independent Director

John Maraganore

Chair of the Board and Independent Director

Laura Tadvalkar

Independent Director

Linda Bain

Independent Director

股东

名称

职位

Benny Sorensen

Chief Executive Officer and Director and President

Ananthram Murthy

Chief Operating Officer

Mads Behrndt

Chief Financial Officer and General Manager

Catherine Madigan

Chief Medical Officer

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/COAG/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"COAG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COAG\",,,,,undefined,":{"symbol":"COAG","market":"US","secType":"STK","nameCN":"Hemab Therapeutics Holdings, Inc.","latestPrice":34,"timestamp":1777665600000,"preClose":18,"halted":0,"volume":4113516,"hourTrading":{"tag":"盘后","latestPrice":33.1,"preClose":34,"latestTime":"19:59 EDT","volume":24517,"amount":807452.3188,"timestamp":1777679985243,"change":-0.9,"changeRate":-0.026471,"amplitude":0.054412},"delay":0,"changeRate":0.8888888888888888,"floatShares":11764706,"shares":39207616,"eps":0,"marketStatus":"休市中","change":16,"latestTime":"05-01 16:00:00 EDT","open":27,"high":36.61,"low":27,"amount":128926048.828896,"amplitude":0.533889,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1777881600000},"marketStatusCode":7,"adr":0,"listingDate":1777608000000,"exchange":"NASDAQ","adjPreClose":18,"postHourTrading":{"tag":"盘后","latestPrice":33.1,"preClose":34,"latestTime":"19:59 EDT","volume":24517,"amount":807452.3188,"timestamp":1777679985243,"change":-0.9,"changeRate":-0.026471,"amplitude":0.054412},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COAG\",,,,,undefined,":{"symbol":"COAG","floatShares":11764706,"roa":"-30.11%","roe":"-46.99%","lyrEps":0,"shares":39207616,"dividePrice":0,"high":36.61,"amplitude":0.533889,"preClose":18,"low":27,"week52Low":27,"pbRate":"-7.55","week52High":36.61,"institutionHeld":0,"latestPrice":34,"eps":0,"divideRate":0,"volume":4113516,"delay":0,"ttmEps":0,"open":27,"prevYearClose":18,"prevWeekClose":18,"prevMonthClose":18,"prevQuarterClose":18,"fiveDayClose":18,"twentyDayClose":18,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/COAG\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"COAG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"COAG\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/COAG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"COAG","date":"2026-05-01","current":-11.042152,"percent":1,"low":-11.042152,"twenty":-11.042152,"median":-11.042152,"eighty":-11.042152,"high":-11.042152,"avg":-11.042152,"sd":0,"marketCap":705737088},"quantilePoints":[{"date":"2026-05-01","current":-11.042152,"twenty":-11.042152,"median":-11.042152,"eighty":-11.042152,"marketCap":705737088}],"updateTime":1777824676343},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1994300807,"yearFounded":2020,"employeeNum":59,"address":"101 Main Street,Suite 1220,Cambridge,Massachusetts,United States","zipCode":"02142","officePhone":"(617) 553-3952","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.hemab.com","stockEarnings":[{"period":"1week","weight":0.8889},{"period":"ytd","weight":0.8889}],"compareEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0998},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.0566},{"period":"1year","weight":0.2904},{"period":"ytd","weight":0.0568}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Hemab Therapeutics Holdings, Inc.于2026年2月12日根据特拉华州法律注册成立。Hemab Therapeutics是一家临床阶段的生物技术公司，致力于开发革新血液凝固障碍治疗的疗法，以帮助维持生命并增强人类的抵抗力。公司的使命是通过发现、开发和商业化创新疗法，为全球患有严重出血和血栓性疾病的患者打造领先的凝血领域公司。这些疾病包括格氏血小板无力症、VII因子缺乏症、血管性血友病以及其他可能造成终身沉重负担的异常出血性疾病。公司的主要候选药物sutacimig (HMB-001) 是一种双特异性抗体，目前正在进行一项针对格氏血小板无力症预防性治疗的I/II期临床试验和一项针对VII因子缺乏症预防性治疗的II期临床试验。","exchange":"NASDAQ","name":"Hemab Therapeutics Holdings, Inc.","nameEN":"Hemab Therapeutics Holdings, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"COAG\",market:\"US\",,,undefined,":{"directors":[{"name":"Benny Sorensen","position":"Chief Executive Officer and Director and President"},{"name":"Akshay Vaishnaw","position":"Independent Director"},{"name":"John Maraganore","position":"Chair of the Board and Independent Director"},{"name":"Laura Tadvalkar","position":"Independent Director"},{"name":"Linda Bain","position":"Independent Director"}],"executives":[{"name":"Benny Sorensen","position":"Chief Executive Officer and Director and President"},{"name":"Ananthram Murthy","position":"Chief Operating Officer"},{"name":"Mads Behrndt","position":"Chief Financial Officer and General Manager"},{"name":"Catherine Madigan","position":"Chief Medical Officer"}]}}}